Answers are grounded in this paper and cite their sources.
After the publication of the pivotal randomized control trials involving extracorporeal membrane oxygenation (ECMO) like the Conventional Ventilatory Support Versus Extracorporeal Membrane Oxygenation for Severe Adult Respiratory Failure (CESAR)1 trial in 2009 and the ECMO to Rescue Acute Lung Injury in Severe ARDS (EOLIA)2 trial in 2018, the use of venovenous ECMO for severe refractory ARDS has seen a significant rise.3 The impact of large viral pandemics such as influenza and COVID-19 also was a notable contributor to the change in ECMO application and its expansion.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: